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Background: p21WAF1 is a potent inhibitor of the
cell-cycle regulatory cyclin-dependent kinases (Cdks).
It acts on Cdks in the G1 and S phases of the cell cycle,
and also binds to proliferating cell nuclear antigen
(PCNA), blocking DNA replication in vitro. Tran-
scription of p21WAF1 can be induced by the human
tumour suppressor protein p53, suggesting that the action
of p21WA F t may be important in cancer prevention. We
have investigated the interaction between p21WAF1 and
PCNA using a genetic two-hybrid screen and with arrays
of synthetic peptides derived from the p21w AFl protein
sequence.
Results: We have established that the carboxy-terminal
region of p2 1WAF1 interacts with PCNA in a yeast two-
hybrid screen. Interaction with p21WAF involves the
central loop of PCNA, which connects the two domains
of the PCNA monomer. The interaction was finely
mapped using peptides derived from the entire sequence
of the p21WAF 1 protein, and the critical residues were
found to be QTSMTDFY (amino acids 144-151 of
p21WAF1). Remarkably, a 20-residue peptide containing
this sequence inhibited replication of simian virus 40
(SV40) DNA in vitro and could capture PCNA from
whole cell extracts, demonstrating that small molecules
can retain the biological activity characteristic of the
whole protein. Sequential alanine-scan mutations of the
peptide demonstrated that its ability to block replication
correlates with its affinity for binding PCNA.
Conclusions: We have shown that PCNA and the cell-
cycle regulator p21WAF1 interact in vivo, and that this
interaction requires the central loop of PCNA and an
eight amino-acid motif from the carboxyl terminus of
p21WAF1. Peptides of p21W AFl that interact with PCNA
can inhibit DNA replication; such peptides or mimetics
may thus prove useful in the treatment of hyper-
proliferative diseases, including cancer.
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Background
Cyclin-dependent kinases (Cdks) are required for certain
key cell-cycle transitions in eukaryotic cells. A family of
small protein inhibitors of Cdks - called CdkIs - ,
have been identified [1]. One of these inhibitors,
p21WAF [2] (also known as p21CiPI [3], p2lPicl [4],
p20CAP [5] and Sdi [6]), seems to be a universal
inhibitor of Cdks; p21W AFI can be transcriptionally
induced by the tumour suppressor protein p53, although
its expression is not always dependent upon p53 [2,7,8].
Thus, p21WAF1 may act to regulate the cell cycle in
response to activation of the p5 3 checkpoint pathway
that responds to DNA damage. [2,7]. The p21WAF1
protein is extremely stable to heat, retaining inhibitory
activity even after treatment at 100 C for 10 minutes [3].
Kinase complexes containing p21WAF can exist in both
catalytically active and inactive forms, suggesting a
subtle regulation of kinase activity by p21WAFI [9]. In
normal human cells, p21WAF1 exists in a quaternary
complex with a cyclin, a Cdk, and the proliferating cell
nuclear antigen (PCNA), although the stoichiometry of
these complexes is not clear [2,3,5,10]. In transformed
cell lines, p2 1WAF l expression is depressed and Cdks
are found in Cdk-cyclin binary complexes rather than
in Cdk-Cyclin-p21WAF1-PCNA quaternary complexes
[2,3,5,10].
PCNA is a processivity factor for DNA polymerase ,
which plays an essential role in DNA replication and
repair [11,12]. PCNA may also be involved in recruiting
replication factors to sites at which DNA replication is
initiated, as PCNA localizes to pre-replicative sites con-
siderably before the onset of DNA replication [13]. The
interaction of p2 1WAF and PCNA blocks the ability of
PCNA to support simian virus 40 (SV40) DNA replica-
tion in vitro without apparently interfering with PCNA's
repair activity [14-17]. In cytoplasmic extracts of Xenopus
eggs that undergo repeated cell cycles in vitro, p2 1W AFl
inhibits replication by acting on cyclin E-Cdk2 to arrest
the cell cycle, rather than by binding directly to PCNA
[18]. This contrast between experimental systems may
highlight yet another mechanism of regulation by
p21WAF1 that depends on post-translational modification
(for example, phosphorylation) of p21W AF 1 and its inter-
acting partners. Various points of the cell cycle are there-
fore amenable to regulation by p2 1WAF1, allowing the
coordination of cell-cycle progression with DNA
replication and repair.
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In this paper, we have used a yeast two-hybrid genetic
screening technique to establish that there is an interac-
tion in vivo between the carboxy-terminal half of
p21WAF1 and the central loop of PCNA that connects the
two domains of the PCNA monomer. We have identi-
fied a small peptide from the carboxy-terminal region of
p21WAF1 that binds to PCNA with high affinity and
selectivity, and we show that its interaction with PCNA
accounts for the inhibition of SV40 DNA replication in
vitro [14,15]. Variants of this peptide have allowed us to
define the residues of p21WAFl that are critical for PCNA
binding, and to show that inhibition of SV40 DNA
replication by p21WAFI is a function of PCNA binding.
A precise understanding of the interaction of p2 1WAF1
with Cdks and PCNA should illuminate its role in coor-
dinating cell proliferation and cell-cycle control. The
high affinity of interaction between PCNA and the
p21WAF1 peptide, and the potent biological activity of the
latter, suggest possible uses for the peptide and mimetics
in tumour therapy.
Results and Discussion
The carboxy-terminal 89 amino acids of p21W AF1 bind
PCNA in an interaction trap
We have screened for proteins that physically interact
with human PCNA using a two-hybrid screening me-
thod that detects polypeptide interactions by means of
the reconstitution of a functional transcriptional activator
in the yeast Saccharomyces cerevisiae [19,20]. A plasmid that
expresses a hybrid protein comprising the DNA-binding
domain of GAL4 (GAL4AS) combined with human
PCNA (pAS-PCNA-Hs) was used to screen plasmids
expressing hybrid fusion constructs made up of DNA
molecules from a human cDNA library and the DNA
encoding the transcriptional activation domain of GAL4
(GAL4ACT); this is known as the pACT-derived library
(Fig. 1 and Materials and methods) [20].
We picked 77 His+ colonies from over 1 x 106 transfor-
mants, of which 14 expressed 13 galactosidase; pACT-
derived library plasmids were isolated from 12 of these
strains which retested positive upon co-transformation
with pAS-PCNA-Hs. Each plasmid encoding a human
PCNA-interacting protein (pHSpip) was tested for non-
specific interactions with other GAL4AS fusions by co-
transforming with various pAS plasmids (Table 1). The
pAS-PCNA plasmids contain the entire open reading
frame of PCNA from Homo sapiens (Hs), Drosophila
melanogaster (Dm) and Schizosaccharomyces pombe (Sp),
respectively, in the vector pAS2. The control plasmids
pAS-SNF1, pAS-lamin, pAS-p53 and pAS-CDK2 are
as described [3]. The plasmids were grouped according
to cross-hybridization and DNA sequence analysis. Each
pHSpip was also tested for interactions with both
D. melanogaster and S. pombe PCNA.
The 12 positives fell into three classes. One class (9 plas-
mids) was shown to contain shared sequences by cross-
hybridization, and will be described elsewhere. A second
class (pHSpip19) showed non-specific interactions with
the control pAS plasmids, and so was not investigated
further. The third class (pHSpip9 and pHSpip31) showed
a specific interaction with pAS-PCNA-Hs. Sequence
analysis (data not shown) indicated that both these
plasmids express the carboxy-terminal 89 amino acids of
Fig. 1. Strategy for detecting PCNA-interacting proteins (Pip)
using the two-hybrid system. The S. cerevisiae strain Y190,
which expresses the reporter genes lacZ (E. col) and HIS3
(S. cerevisiae) under the control of the GAL 1 promoter was used
to detect the reconstitution of GAL4 activity using the two-hybrid
system . Y1 90 was co-transformed with pAS-PCNA-Hs (encoding
the DNA-binding domain of GAL4 (amino acids 1-147, GAL4As)
fused to human PCNA) and also with the pACT-derived human
cDNA library which expresses human proteins as fusion con-
structs ,with the activation domain of GAL4 (amino acids
768-881) [20]. Tranformants containing library-encoded PCNA-
interacting proteins result in the reconstitution of GAL4 activity,
and thus in the expression of reporter constructs.
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Fig. 2. Identification of the regions of PCNA that interact with p21WAF1. The structural domains within the PCNA molecule are shown.
Numbers indicate p-sheet domains and a helices based on the three-dimensional structure of S. cerevisiae PCNA [23]. Bars below
indicate the regions of PCNA expressed as fusions with GAL4ACT, and the column on the right (+/-) indicates a positive/negative result
when tested for interaction with p21WAF1 in the two-hybrid system.
p21WAF 1 [3,5,10] in frame with GAL4ACT, although the
vector sequences of one of the plasmids showed a slight
rearrangement. A p21WAF1 construct encoding the full-
length protein in frame with GAL4ACT interacted with
both Cdk2 and PCNA in the two-hybrid system,
although the carboxy-terminal half of p21WAF1 did not
interact with Cdk2. This is the first report of an inter-
action between p21WAFI and PCNA in vivo, and shows
that the carboxy-terminal half of p2 1WAF1 is sufficient for
this interaction.
PCNA-PCNA interactions
We undertook a similar screen to search for S. pombe
cDNAs encoding proteins that would interact with
S. pombe PCNA (encoded by pcnl+ ) [21]. Two of the
clones identified expressed the entire open reading frame
of pcn 1+ (data not shown), suggesting that PCNA is able
to interact with itself. These results are consistent with
the model proposed by Kong et al. [22], which is sup-
ported by evidence from Krishna et al. [23], in which
PCNA forms a homotrimer that acts as a sliding clamp,
tethering the replication complex to the DNA strand.
Furthermore, the pcnl+ product was found to interact
with both human and D. melanogaster PCNA, suggesting
that the interaction is evolutionarily conserved (Table 1).
Human PCNA has sufficient DNA-binding capacity for
a PCNA-GAL4ACT hybrid to activate reporter gene
expression in the two-hybrid system, so such a construct
could not be used for two-hybrid interaction analysis
(data not shown).
p21WAF1 interacts with the central region of PCNA
We next tested a series of carboxy-terminal deletion
constructs of human PCNA fused to GAL4As, in order
to identify the regions of PCNA that interact with
p21WAFl in the two-hybrid assay [20]. The results of
these experiments (Fig. 2) suggest that p21WAF1 inter-
acts with a central region of PCNA. Structural and
sequence similarities between the 3 subunit DNA poly-
merase III of E. coli and PCNA have suggested a model
in which three PCNA subunits, each consisting of two
repeated domains, form a toroid structure that encircles
the DNA strand [22]. The three-dimensional structure
of S. cerevisiae PCNA has recently been described [23],
and this molecule does indeed form a trimeric ring with
close topological symmetry to the 3 subunit of DNA
polymerase III, although the sequence alignment on
which the previous model was based has been found to
be largely incorrect. The data in Figure 2 are consistent
with p21W AF 1 interacting with the 'junctional loop' that
connects the two domains.
Peptide mapping of sites on p21WAF1 important for its
interaction with PCNA
In order to refine the map of the site(s) on p21WAF1 that
interact with PCNA, we tested the binding capability of a
series of 11 overlapping 20-residue peptides derived from
the p21WAFl sequence (Fig. 3a). This approach has been
used successfully to fine-map protein-protein interactions
(for example, the interaction between p53 and MDM2)
and antibody epitopes [24-26]. The p21WAFa peptides
were linked to biotin, permitting attachment to strepta-
vidin-coated ELISA plates (see Materials and methods).
PCNA from various sources, including HeLa cell extract,
Xenopus egg extract and lysate of E. coli BL21 over-
expressing a human PCNA clone [27], were applied to
the immobilized peptide array. Bound PCNA was
detected using the polyclonal antibody 3009, which rec-
ognizes the carboxy-terminal 15 amino acids of native
and denatured PCNA (L.S.C., S. Picksley, P.A. Hall,
A.T.M. Rennie and D.P.L., unpublished data). PCNA
from the three sources tested binds with great specificity
to peptide 10 (KRRQTSMTDFYHSKRRLIFS in the
single-letter amino-acid code; Fig. 3b), which we
designate p21PBP (for p21WAF1 PCNA-binding peptide).
The interaction of PCNA with the adjacent peptide 11,
which shares all but the initial four residues with peptide
10, is much weaker (13 % of the level of binding for bac-
terially expressed PCNA, and only 3.8 % for HeLa
PCNA), suggesting that some or all of the residues
KRRQ are important in determining the affinity of
p21WAF1 for PCNA. Similar results were obtained when
the monoclonal antibody PC10 was used to detect
PCNA [28], demonstrating that the interaction between
PCNA and p21PBP of p21WAFl is specific to PCNA and
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Fig. 3. Peptides of p21WAF1 and analysis of PCNA binding by
ELISA. (a) Peptides 1-11 cover the entire protein sequence of
p21WAF1 [2], with overlaps between adjacent peptides. Peptide
63 represents the carboxy-terminal 15 amino acids of PCNA. (b)
Peptides were incubated with cell extracts from HeLa, Xenopus or
E.coli BL21 cells overexpressing human PCNA, and binding was
assessed by ELISA (OD 450 nm). (c) Purified human PCNA from
BL21 cells was compared with crude lysates, as in (b) above.
PCNA was detected using polyclonal anti-PCNA antibody 3009.
not due to antibody cross-reaction. This specificity was
confirmed using purified PCNA which bound strongly
and specifically to p21PBP (Fig. 3c). This result also
confirms that the interaction detected in the two-hybrid
screen was direct and not mediated by a bridging protein.
Fig. 4. Mapping the sites of p21WAF1 required for PCNA binding
using precipitation analysis. (a) All 11 peptides of p21WAF1,
separately attached to streptavidin-agarose beads, were incu-
bated in HeLa cell extract; beads were then separated from the
lysate by centrifugation. Bound proteins were analysed by SDS
polyacrylamide gel electrophoresis, and then western
immunoblotted with PC10 monoclonal anti-PCNA antibody fol-
lowed by horseradish peroxidase-anti-mouse secondary anti-
body and enhanced chemiluminescent (ECL) detection. Peptides
are numbered as in Fig. 3a. H indicates undepleted HeLa
extract. Molecular weight marker sizes are shown in kD on the
left. The position of PCNA is marked by an arrow. (b) Western
blot probed with monoclonal antibody PC1 0, and
(c) Coomassie-stained gel of p21 PBP-streptavidin bead precipi-
tation from extracts of various human tumour cell lines. The
results from seven out of fourteen lines tested are shown; A431
(sample 1), HOS (sample 2), SKBR3 (sample 3), BT549 (sample
4), MDA231 (sample 5), T47D (sample 6) and DLD1 (sample 7).
Similar results to those shown were found for the remaining
seven lines (data not shown). S indicates supernatant after incu-
bation with p21PBP beads; B contains proteins precipitated by
the p21 PBP-streptavidin agarose beads; M shows the position of
molecular weight standards and sizes are given in kD.
p21WAFI peptides can precipitate PCNA from cell extracts
To confirm the specificity of the interaction between
native PCNA and p21WAFl peptides, the peptides were
attached to streptavidin-agarose beads and incubated
in HeLa cell extract. The proteins that bound to the
beads were separated electrophoretically, blotted onto
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nitrocellulose, and probed with the anti-PCNA mono-
clonal antibody PC10 (Fig. 4a). PCNA was precipitated
by beads carrying p21PBP, aifd also weakly by peptide
11. The p21PBP precipitate contained a similar amount
of PCNA to the untreated control extract (HeLa), sug-
gesting a highly efficient capture of soluble PCNA. By
contrast, PCNA was not detected in the precipitates of
any other p21WAF1 peptide.
PCNA could be quantitatively removed from extracts of
14 other human tumour cell lines by p21PBP (7 are
shown in Fig. 4b). In some cases, such as SKBR3 and
BT549 cells, there was almost complete transfer of
PCNA from the cell lysate to the beads. This result sug-
gests that PCNA from these tumour cell lines is not
altered in its ability to bind p21WAF1. Parallel gels stained
with Coomassie brilliant blue show that the interaction
with PCNA is highly specific, as the amount of total pro-
tein precipitating with the beads is negligible (Fig. 4c).
The interaction of PCNA with the p21PBP peptide
could not be disrupted using 100 mM glycine pH 2.5,
100 mM triethylamine pH 12.5 or 1.4 M NaC1 under
batch elution conditions (data not shown), demonstrating
the strength of the binding. Strong binding could even
be detected when only 500 pg of peptide was applied to
the wells in the ELISA assay. These results suggest that
p21PBP beads may be used to deplete cell extracts of
PCNA, and should therefore prove to be a useful tool in
further elucidating the action of PCNA in DNA
replication and repair.
Inhibition of SV40 DNA replication by p21 PBP
As p21WAF1 has recently been reported to bind PCNA
and to inhibit the replication of SV40 DNA [14,15], we
examined the 20mer peptides for their effect on the
replication of SV40 DNA in vitro (Fig. 5a). Of all the
peptides, only p21PBP (peptide 10) had a significant
effect on DNA replication in vitro, reducing incorpora-
tion of [3 H]dTMP to 51 % of control levels at
20 Ig ml-1 and to 31 % of control values at 40 Lg ml-1.
The concentration-dependence of the inhibition of
replication by p21PBP is shown in Figure 5b. The activ-
ity is remarkably high for a peptide: DNA replication is
inhibited at 25 ,ug ml-1 (12.5 iM), which is only a ten-
fold higher molar ratio than the full-length p21WAF 1 pro-
tein used by Waga et al. [15]. It is remarkable that a small
peptide shows any activity in this biological assay, and the
finding that this peptide that can inhibit DNA replica-
tion, and can bind to PCNA in tumour cell extracts,
raises important therapeutic possibilities.
The minimum PCNA binding site on p21WAF1
The sequence of p21PBP was scanned to determine the
minimum size of the recognition sequence by creating a
set of 20mer peptides with 4 amino-acid overhangs (that
is, with a 16 amino-acid overlap between adjacent pep-
tides). These were based on the p21WAF1 sequence from
amino acids 121-164, and included the initially identified
reactive peptide (p21PBP) of sequence KRRQTSMTD-
FYHSKRRLIFS (Fig. 6a). These peptides were immobi-
lized on streptavidin-coated ELISA dishes, and screened
for binding to PCNA over-expressed in E. coli BL21. Of
the eight peptides in this array, only peptides 68, 69, and
70 bound strongly to PCNA (Fig. 6b). Of these three,
peptide 70 (identical to p21PBP) gave the highest signal.
These peptides were also tested for their ability to inhibit
the replication of SV40 DNA in vitro. Of all the peptides,
only peptide 70 (p21PBP) showed any appreciable
inhibitory activity, although a slight decrease in label
incorporation was observed with peptide 71 (Fig. 6b).
Fig. 5. Inhibition of DNA replication by p21PBP. (a) All peptides of p21W AF1 were added individually to an SV40 DNA replication
reaction in vitro, to a final concentration of 20 pzg ml-1 (grey columns) or 40 Ipg ml-1 (black columns), compared with DMSO at equiv-
alent dilutions, or with no addition (duplicate result, white columns). After a 2 hour incubation at 37 C, incorporation of [3H]dTMP
was measured by TCA precipitation and scintillation counting. (b) p21 PBP (peptide 10) was added to the replication reaction at a range
of concentrations up to 30 ig ml-1 and compared with equivalent dilutions of the solvent DMSO. The extent of label incorporation
was analysed after 2 hours as above. The same concentrations of peptide 9 (data not shown) or the solvent alone had no appreciable
effect on levels of DNA synthesis.
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Fig. 6. Determination of the minimal
binding site of PCNA on p2lWAF1. (a) A
series of 20mer peptides covering
p21 PBP were synthesized with 4
amino-acid overhangs (16 amino-acid
overlaps) (b) These peptides were used
to coat ELISA dishes and the binding of
bacterially expressed PCNA was
detected by antibody 3009. Optical
density at 450 nm after colour develop-
ment is plotted as bars for each of the
peptides. In a separate experiment,
these peptides were added at
40 pg ml-1 to SV40 DNA replication
reactions in vitro, and the percentage
inhibition of label incorporation, calcu-
lated against the 'no addition' positive
control, is plotted in red.
Interestingly, neither peptide 68 nor peptide 69 showed
any capacity to block SV40 DNA replication, despite the
ability of each to bind PCNA. Using a modified form of
p21PBP with an additional four amino acids at the
amino terminus and a concomitant loss of four carboxy-
terminal arhino acids, the relationship between PCNA
binding and inhibition of replication was not so straight-
forward. These results confirm our earlier observations
that the motif KRRQTSMTDFYH is required for bind-
ing to PCNA, but that the more carboxy-terminal
residues SKRRLIFS also contribute to the biological
activity of p21WAFI.
Critical residues within p21 PBP
In order to define the critical residues within the PCNA
binding site of p21WAF1, a series of peptides was gener-
ated in which each residue of p21PBP was altered se-
quentially to alanine; a double mutant with two arginines
substituted by alanine was also made. In addition, a pep-
tide was generated containing the same amino acids as
p21PBP but in a different order ('jumbled p21PBP').
These peptides were tested in the ELISA for PCNA-
binding capacity. It was found that residues M and F were
absolutely required for recognition, whereas mutation of
Q, D or Y considerably decreased the ability to bind
PCNA (Fig. 7). Jumbled p21PBP did not bind PCNA,
indicating that the order of amino acids as well as the
overall composition is important for p21PBP activity. In
general, of these altered peptides, those with the strongest
PCNA-binding activity were most able to inhibit SV40
DNA replication in vitro, and conversely, loss of PCNA
binding correlated with lack of inhibition of SV40 DNA
replication (Fig. 7). These results allow us to define the
region of p21WAF1 involved in PCNA binding as
QTSMTDFY. The residues shown in bold are critical
for PCNA binding, and those underlined are important.
Phosphorylation of the serine and threonine residues
within this motif could regulate PCNA binding to
p21WAF1, and it is also interesting to note that this motif
lies within a consensus bipartite nuclear localization
signal [29]. We are currently investigating the possibility
that modification of these sites may alter the
stoichiometry of 21WAFl-cyclin-Cdk-PCNA complexes.
Fig. 7. Alanine scanning to determine the critical residues of
p21PBP. Peptide variants of p21PBP were generated with
sequential alanine changes, or with two arginines (residues 2 and
15 in the peptide) altered to alanine. The efficiency of binding of
these peptides to bacterially expressed PCNA was tested by chro-
mogenic ELISA, and the optical density at 450 nm is shown by
the shaded bars. These peptides were also tested for their ability
to inhibit SV40 DNA replication in vitro, calculated against the
'no peptide' control, and shown by the red line; 'jumbled
p21 PBP' contains the same amino acids as p21 PBP, but in the
order QDKTRYFHRTMSRSKSIRLF, and p21PBP* is the same
sequence as p21 PBP but from a different peptide synthesis batch.
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Conclusions
We have demonstrated a-strong interaction between the
central loop of PCNA and the carboxy-terminal region
of p21WAF1 using the yeast two-hybrid screening
method. A 20 amino-acid peptide, p21PBP, that is
derived from p2 1WAF1, binds to PCNA strongly and
specifically and is capable of inhibiting DNA replication
in vitro. Knowledge of the critical sites for
p21WAF1-PCNA interaction and function should assist
searches for mutations in the genes encoding these vital
cell-cycle regulators in human tumours. Our results lead
us to suggest that p21PBP itself, or its derivatives or
mimetics, might be used therapeutically. Drugs based on
p21PBP may be capable of functionally down-regulating
PCNA replication activity in tumour cells. As such ther-
apy would reinforce the endogenous cell-cycle regulatory
pathway without impairing DNA repair, we anticipate
that hyperproliferation could be checked whilst genomic
integrity is maintained.
Materials and methods
Cloning and expression plasmid construction
Manipulation of E. coli and DNA was by standard methods
[30]. All plasmid constructs containing fragments produced by
the polymerase chain reaction (PCR) were initially subcloned
into pBC-SK (Stratagene) and sequenced using oligonucleotide
primers on one strand to check for PCR errors before a second
step of subcloning into the required expression vector. DNA
sequencing was performed using double-stranded plasmid tem-
plate DNA with a modification of the Sequenase protocol
(USB). Sequence analysis was carried out using the UWGCG
package at the Daresbury Seqnet facility. The human PCNA
open reading frame was adapted as NdeI-BamHI fragments
using PCR, to give either the full-length open reading frame,
or the deletion constructs described in Figure 2. One full-
length isolate was used to subclone the insert into pAS2 [3] to
give pAS-PCNA-Hs, and also into the vector pREP1 which is
used for expression in S. pombe under the control of the nmtl
promoter [31]. This plasmid, pREP1-PCNA-Hs, was capable
of complementing the lethality resulting from pcn I deletion,
suggesting that the protein expressed from this construct is
functional. The plasmid pAS-PCNA-Sp was derived from the
plasmid pREPlpcnl [21]. The insert in this plasmid was found
to contain a frameshift mutation compared to the genomic
sequence (data not shown) and was modified before cloning
into pAS2 to ensure that the entire protein was expressed. The
plasmid pAS-PCNA-Dm was constructed in a similar fashion
to that described above. The full-length open reading frame of
p21WAF1 was cloned as a BamHI fragment using PCR. This
was subcloned into the BamHI site in pACT to give plasmids
pACT-p21 The S. pombe expression library was constructed in
pACT and was a gift from Steve Elledge.
Yeast two-hybrid methods
Growth and maintenance of S. cerevisiae was according to Rose
et al. [32]. Transformation was carried out by the method of
Gietz et al. [33]. All growth was carried out at 30 °C. The
S. cerevisiae strain Y190 (MATa leu2-3, 112, ura3-52, trpl-901,
his3-D200, ade2-101, gal4D, gal80 D, cyhR URA3::GALI-
lacZ, LYS2::GALI-HIS3) was used for all two-hybrid analysis.
This strain expresses the reporter genes lacZ (E. colt) and HIS3
(S. cerevisiae) under the control of the GALl promoter.
Expression of lacZ was assayed by a filter-lift assay for a galac-
tosidase [34]. The HIS3 reporter construct described here gives
residual HIS3 expression, although not sufficient to render the
cells resistant to 3-aminotriazole, a chemical inhibitor of HIS3
(IPG dehydratase) at 50 mM. In order to test for HIS3 expres-
sion from the GALI promoter, cells were streaked out on
SDA [32] plates containing 50mM 3-aminotriazole, incubated
for 1 week, and plates examined for the formation of single
colonies. Where growth occurred, a filter-lift was taken from
these plates to assay [ galactosidase activity. Only transformants
which expressed both reporter genes were counted as true pos-
itives. Plasmid DNA was recovered from S. cerevisiae using a
modified version of the method described by Hoffman and
Winston [35] and further purified using GeneClean
(Stratagene). The E. coli strain JA226 (recBC leuB6 trpES hsdR-
hsdM+ lacY600) was used; ampicillin-resistant colonies were
tested for leucine prototrophy to determine whether they con-
tained a pACT or pAS2 derived plasmid, as the LEU2
sequences in pACT complement the leuB6 mutation in JA226.
Two-hybrid screening
Y190 transformed with pAS-PCNA-Hs was tested and found
not to express either of the reporter constructs in this strain.
This transformant strain was then itself transformed with a
human cDNA library in the vector pACT, which has cDNAs
expressed as fusion constructs with the activation domain of
GAL4 (amino acids 768-881) [20]. Transformants containing
library-encoded PCNA-interacting proteins result in the
reconstitution of GAL4 activity, and thus in the expression of
reporter constructs. These were selected for by plating on SDA
containing 3-aminotriazole, while an aliquot was plated on
SDA without 3-aminotriazole to determine transformation fre-
quency. Putative positives were tested for lacZ expression,
streaked out on SDA containing 3-aminotriazole, and a single
colony isolated for further analysis; cDNA library plasmids
were rescued into E. coli strain JA226.
Peptides and ELISA
Peptides were synthesized (Chiron Mimotopes, Australia) to
cover the wild-type p21W AF1 protein sequence, with 5 or 16
amino-acid overlaps, linked at their amino termini to biotin by
a 4-amino-acid linker of sequence SGSG. An alternative set of
peptides was also generated, in which each residue from amino
acids 144-164 was substituted in turn by alanine. Peptides were
dissolved in DMSO at 5 or 10 mg ml-1 and stored at -80 °C.
Plastic plates for ELISA (enzyme-linked immunoabsorption
assay; Falcon) were coated overnight at 37 °C with 5 g ml-1
streptavidin (Vector), washed with PBS plus 0.2 % Tween 20
(PBST) then blocked in 5 % non-fat milk powder inr PBS
(milk-PBS) for 2 h at room temperature (r.t.). Each well of the
plates was incubated with the following, washing extensively
with PBST between each incubation : (i) 0.5 pxg peptide
diluted in 0.1 % milk-PBS, 1 h, r.t.; (ii) -6 Rg total protein
from cell extracts diluted in 0.1 % milk-PBS, 1 h, r.t.; (iii) pri-
mary antibody 3009 diluted 1:1000 in 2 % milk-PBST or undi-
luted hybridoma supernatant of PC10, 1 h, r.t.; (iv) secondary
horseradish peroxidase conjugated anti-rabbit (for 3009) or
anti-mouse (for PC10) antibody at 1:1000 in 2 % milk-PBST,
1 h, r.t.; then 50 R.1 of the chromogenic substrate TMB was
added per well (prepared from 10 mg ml-1 stock in DMSO and
diluted to 100 pxg mi-1 final concentration in 0.1 M sodium
acetate, pH 6.0, with 1:1000 diluted 30% stock solution
H20 2). Once a visible blue colour had developed, the reaction
was stopped by addition of approximately 1 M H2SO 4, and
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282 Current Biology 1995, Vol 5 No 3
the plate read using a Dynatech 5000 ELISA plate reader
at 450 nm. Human PCNA was purified from lysates of BL21
transformed with the pT7.7hPCNA construct [27].
Peptide precipitation of PCNA
Peptide (1.5 pg) was bound to 10 p}l packed streptavidin-
agarose beads for 1 h at room temperature. The beads were
washed extensively in PBS prior to incubation with 20 Rg total
cell protein for 1 h at 4 C. After washing three times in 1.5 x
PBS (220 mM NaC1), the beads were boiled in loading buffer
(0.2 M dithiothreitol, 2% SDS, 1% bromophenol blue and 20%
glycerol) and then proteins were separated by 10 % SDS poly-
acrylamide gel electrophoresis and either stained directly with
Coomassie brilliant blue or electrophoretically transferred onto
nitrocellulose. Blots were blocked in 5 % milk-PBST, washed
in PBS and incubated with undiluted culture supernatant from
PC10 hybridomas, followed by horseradish peroxidase-conju-
gated rabbit anti-mouse antibody (Dako) at 1:1000 dilution in
2 % milk-PBST. Proteins were visualised by the enhanced
chemiluminescence (ECL) reaction using Hyperfilm-MP
(Amersham, UK).
Replication reactions
SV40 DNA replication reactions were carried out essentially
as described by Wang et al. [36] with the exception that all
incubation volumes were 10 l.
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